1 Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
2 Respiratory, Inflammation, and Autoimmunity, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts.
Am J Respir Crit Care Med. 2018 Feb 15;197(4):433-449. doi: 10.1164/rccm.201703-0615CI.
Important features of both stable and acute exacerbation of chronic obstructive pulmonary disease (COPD) are skeletal muscle weakness and wasting. Limb muscle dysfunction during an exacerbation has been linked to various adverse outcomes, including prolonged hospitalization, readmission, and mortality. The contributing factors leading to muscle dysfunction are similar to those seen in stable COPD: disuse, nutrition/energy balance, hypercapnia, hypoxemia, electrolyte derangements, inflammation, and drugs (i.e., glucocorticoids). These factors may be the trigger for a downstream cascade of local inflammatory changes, pathway process alterations, and structural degradation. Ultimately, the clinical effects can be wide ranging and include reduced limb muscle strength. Current therapies, such as pulmonary/physical rehabilitation, have limited impact because of low participation rates. Recently, novel drugs have been developed in similar disorders, and learnings from these studies can be used as a foundation to facilitate discovery in patients hospitalized with a COPD exacerbation. Nevertheless, investigators should approach this patient population with knowledge of the limitations of each intervention. In this Concise Clinical Review, we provide an overview of acute muscle dysfunction in patients hospitalized with acute exacerbation of COPD and a strategic approach to drug development in this setting.
慢性阻塞性肺疾病(COPD)稳定期和急性加重期的重要特征均为骨骼肌无力和消耗。急性加重期时的肢体肌肉功能障碍与各种不良结局相关,包括住院时间延长、再入院和死亡。导致肌肉功能障碍的因素与稳定期 COPD 中所见的因素相似:废用、营养/能量平衡、高碳酸血症、低氧血症、电解质紊乱、炎症和药物(即糖皮质激素)。这些因素可能是局部炎症变化、途径过程改变和结构降解下游级联反应的触发因素。最终,临床影响可能广泛,包括肢体肌肉力量减弱。目前的治疗方法,如肺部/物理康复,由于参与率低,效果有限。最近,在类似疾病中开发了新型药物,这些研究中的经验可以作为基础,促进 COPD 急性加重住院患者的发现。然而,研究人员应该了解每个干预措施的局限性,对这一患者群体进行研究。在本简明临床综述中,我们概述了 COPD 急性加重住院患者的急性肌肉功能障碍,并对该治疗环境中的药物开发提出了策略性方法。